This two-day course is designed to provide faculty and physicians-in-training an overview and update on the diagnosis and management of sarcoidosis and other interstitial lung diseases (ILDs) amidst the novel coronavirus disease 2019 (COVID-19) pandemic. Because of lower pulmonary and cardiac reserve and due to medications which suppress the immune system, infections can be more severe in patients with sarcoidosis and other ILDs. The novel pandemic coronavirus, has caused medical and economic crises around the globe. Studies querying how viral respiratory infections impact the care and clinical course of patients with sarcoidosis and other ILDs – e.g. preemptive adjustment of immunosuppressive medications – are ongoing. The predilection for extrathoracic involvement in sarcoidosis, and in particular cardiomyopathy, adds an extra dynamic with the risk for coronavirus fulminant myocarditis. Furthermore, patients with COVID-19 severe acute respiratory distress syndrome (SARS) are at risk for developing ILD. The course will involve lectures delivered by experts in the field, highlighting clinical and treatment features having an impact on both the risk for infection and risk for poor outcome among patients with sarcoidosis or other ILDs as well as general updates on screening practices and treatment.